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Objective: The objective of this study was to determine
the relationship between drug-related problems (DRPs)
and health-related quality-of-life (HRQoL) in ambula-
tory, community-dwelling patients with musculoskeletal
disorders.
Methods: A 12-month, prospective, observational study
was conducted in 12 independent community pharmacies
in eastern Iowa. Ambulatory patients with self-reported
diagnoses of osteoarthritis, rheumatoid arthritis, or low
back pain were invited to participate. During quarterly
visits to the pharmacy, patients used touch-screen com-
puters to ﬁll out the Short Form-36 (SF-36) general health
survey. Using the results of these point-of-service health
status assessments, community pharmacists interviewed
patients to assess for DRPs. To examine the inﬂuences of
different DRP characteristics on HRQoL and controlling
for potential confounders, both univariate and multivari-
ate analyses were performed using the change in physical
component summary (PCS) score and mental component
summary (MCS) score of the SF-36 from baseline to 12
months as the dependent variables. In each regression, the
independent variables were those signiﬁcant variables
from the univariate analyses, as well as the types of DRPs
and their outcomes.
Results: A total of 461 patients were enrolled in the 
study. Through 12 months, 926 cumulative DRPs were
identiﬁed. Overall regression models were signiﬁcant 
for the PCS and MCS scores, respectively. Two types 
of DRPs showed signiﬁcant negative associations with
change in PCS: wrong drug and needs additional drug
therapy. One type of DRP showed signiﬁcant negative
association with change in MCS: needs additional drug
therapy. Resolution or improvement in DRPs showed a
signiﬁcant positive correlation with change in MCS but
not PCS.
Conclusions: Two DRPs, needs additional drug therapy
and wrong drug, are associated with reduced self-
reported physical health in arthritis and low back pain,
while the DRP needs additional drug therapy is also asso-
ciated with reduced self-reported mental health. Resolu-
tion of DRPs is associated with improvement in mental
health in this cohort.
Keywords: drug-related problems, quality of life, arthri-
tis, pharmacists.
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ABSTRACT
Introduction
Economic and clinical outcomes of medical care are
traditionally considered in tandem when examining
the health of individual patients or populations.
These two types of outcomes, however, fall short in
evaluating the entire spectrum of health. A third
health outcome is the patient-reported, humanistic
outcomes of medical care. One popular example 
of such an outcome, health-related quality of life
(HRQoL), describes the patient’s perspective of
their disease and treatment, their perceived need for
health care, and preferences for treatment and out-
comes [1,2]. The relationship among the clinical,
economic, and humanistic outcomes of medical
therapy is an important consideration when seek-
ing to optimize pharmacotherapy regimens. For
example, an antihypertensive drug may reduce
blood pressure but cause harmful side effects that
decrease overall well-being. The medication may be
so costly that the patient must decide whether to
pay for the medication or some other essential item,
such as groceries.
A recent Institute of Medicine report highlighted
the importance of medical errors in the health-care
system [3]. Many of these errors are drug-related.
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These drug-related problems (DRPs) are increas-
ingly recognized to have signiﬁcant morbidity and
mortality and contribute to rising health care
expenditures [4–8]. Drug-related problems gener-
ally fall into categories of 1) overuse of medications
(polypharmacy), which increases the likelihood of
adverse events or drug interactions; 2) underuse of
medications, where diseases are not treated with
adequate doses of medication or conditions requir-
ing treatment are not currently treated [9,10]; or 3)
inappropriate prescribing, which refers to medica-
tions with low margins of safety that should always
be avoided [11]. It is important that patients re-
quiring multiple medications for their illnesses be
systematically monitored for potential and existing
DRPs that could impact their perceptions of their
quality of life. Although adverse outcomes of
medical care, including DRPs, are well studied in
the hospital setting [6,12,13], there is a lack of
information about the impact of DRPs and its rela-
tionship to patient-reported outcomes in ambula-
tory settings.
In a prospective, observational study of ambula-
tory community-dwelling arthritis sufferers, we
highlighted the use of community pharmacies as a
unique and efﬁcient site to systematically collect
patient-reported outcomes of medical care [14,15].
These point-of-care health status assessments were
found to contribute to the pharmacists’ ability to
identify DRPs. The relationship of these DRPs to
HRQoL has not been investigated. Arthritis ill-
nesses account for signiﬁcant health burden and
reduced quality of life in the United States, result-
ing in annual expenditures of nearly $65 billion
[16,17]. It is probable that these patients are at risk
for medication-related morbidity because they often
require therapy with multiple drugs that have sig-
niﬁcant toxicities. However, no studies have directly
examined the link between DRPs and HRQoL in
this population. Because an important goal of initi-
ating drug therapy for treatment of chronic illnesses
such as arthritis is to improve humanistic outcomes,
it is of paramount concern to understand the poten-
tial negative impact of DRPs on HRQoL. The
objective of this analysis was to investigate the rela-
tionship between DRPs and HRQoL in a cohort of
arthritis and low back pain sufferers.
Methods
This was a 12-month prospective study beginning
in February 1999 with a 6-week enrollment period.
Twelve community pharmacies, which are con-
stituents of the Outcomes Pharmaceutical Health
Care Certiﬁed Pharmaceutical Care Network, par-
ticipated in this study. The community pharmacies
were located in eastern Iowa towns ranging from
3,500 to 110,000 persons.
Eligible patients were invited to participate if
they met the following inclusion criteria: 1) new 
or established patients of the pharmacy; 2) docu-
mented of having received a minimum of a 3-month
supply in the past 12 months of any nonsteroidal
anti-inﬂammatory drug (NSAID), narcotic, or non-
narcotic analgesic (e.g., codeine, acetaminoiphen,
tramadol) for the management of musculoskeletal
disorders, speciﬁcally osteoarthritis, rheumatoid
arthritis, or low back pain; 3) age of 18 years or
older; 4) noninstitutionalized and willing to fulﬁlll
the visit requirements; 5) able to read, write, and
understand English; and 6) willing to provide
informed consent to participate in this study. A
central institutional review board approved the
study, and all patients provided informed consent to
participate.
At baseline and at each quarterly follow-up visit
to the pharmacy for 1 year, patients completed the
Short Form-36 (SF-36) general health survey [18]
and answered questions about health-care resources
used in the past 3 months, functional limitations
associated with arthritis and low back pain, and
side effects of their prescribed medications.
The Touch Outcomes Collector (Assist Tech-
nologies, Scottsdale, AZ) was utilized to administer
the SF-36 survey and document patient-speciﬁc visit
information. The touch-screen computer has the
capability of administering and recording survey
questionnaires in a longitudinal fashion and pro-
viding real-time data processing at the completion
of the survey. Each pharmacy had a terminal and
printer installed in a semiprivate location within the
pharmacy. Touch-screen technology was chosen for
ease of data collection, real-time accessibility, cost-
effectiveness, and patient acceptability [19,20]. 
In addition to advantages of eliminating the need
for paper surveys or mailed questionnaires, touch-
screen technology was employed because some
patients with arthritis and other musculoskeletal
disorders would be expected to have difﬁculty using
pen or pencil to complete surveys. Both patients and
pharmacists provided data at each visit. A standard
list of comorbid illnesses and demographics were
asked at baseline. At each visit, the pharmacists
documented prescription and over-the-counter
medications taken by the patient into the touch-
screen computer. The information entered each time
into the patient ﬁle in the touch-screen computer
was carried forward through each visit.
After the patient completed the questionnaire,
two reports were immediately printed by the com-
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puter and were used by the pharmacist as a focus
for identifying DRPs. One report highlighted
responses that were identiﬁed a priori by study
investigators as clinically important indicators of
functional status and health resource utilization.
The other report included a graph of the patient’s
SF-36 health survey scores compared to age and sex
adjusted population norms and all their previous
visit scores.
The pharmacist reviewed the reports with the
patient to determine if there were any health or
medication issues that should be addressed. As part
of the drug therapy assessment, the pharmacist used
the same touch-screen system to document pre-
scription and nonprescription medication use, any
DRPs identiﬁed, and disease state to which each
DRP was related, as well as any interventions or
actions to resolve the DRPs, into a ﬁle linked to the
patient survey. Drug-related problems were catego-
rized into one of seven categories adapted from
Strand et al. [9]. These categories are needs addi-
tional drug therapy, adverse drug reaction, dose too
low, dose too high, inappropriate compliance,
wrong drug, and unnecessary drug therapy.
After identifying DRPs, pharmacists initiated
processes to resolve the identiﬁed DRPs at their dis-
cretion. Although pharmacists could make recom-
mendations regarding prescription drug regimens to
the patient’s primary care physician, the physician
performed all adjustments to the therapy. At the
next follow-up visit, the outcome of each DRP was
reported as resolved, improved, stable/unchanged,
or worsened and recorded into the computer.
The measures of HRQoL used in the analyses
were the physical component summary (PCS) and
the mental component summary (MCS) of the SF-
36. These component scores aggregate the eight
scales of the SF-36 into a measure of physical health
status and a measure of mental health status
[21,22]. This approach limits the chance for ﬁnding
aberrant statistical signiﬁcance that might occur
with multiple tests required for examination of each
domain of the SF-36 as a dependent variable. Also,
the use of the component summaries can simplify
interpretation of ﬁndings. Because PCS and MCS
scores result from aggregation and weighting of
individual SF-36 domains, these summary scores
should reﬂect a comprehensive view of the patient’s
quality of life.
To examine the association between HRQoL and
DRPs, a change score was individually calculated
for the PCS and the MCS by subtracting the base-
line score from the 12-month score. Two multivari-
ate regressions were performed, one in which the
dependent variable was change in PCS and another
in which the dependent variable was change in
MCS. Univariate correlations, using Spearman’s
rho, were performed ﬁrst between these difference
scores and a set of baseline patient characteristics.
Those baseline patient characteristics signiﬁcant at
P < .05 in the univariate analyses were then selected
along with the cumulative 12-month frequencies of
the seven categories of DRPs and the four DRP out-
comes for inclusion in the ﬁnal multivariate models.
Information on type of DRP and outcome in the
univariate analyzes was not included, because the
relationship between these variables and change 
in PCS or MCS is the focal point of interest for the
multivariate analyses. Because previous research
has not shown one type of DRP or outcome to be
more or less associated with changes in the HRQoL
than another, we believed it was important to retain
the DRP variables in the ﬁnal model.
The baseline patient characteristics were grouped
into the following main categories: demographics,
comorbid illnesses, site/type of musculoskeletal
disease, potential arthritis medication-related
adverse effects, and health utilization. Many of
these control variables have been previously associ-
ated with HRQoL for arthritis and other chronic
conditions, and our analytic approach recognized
this [17,21–26]. The speciﬁc composition of the
baseline patient characteristics included demo-
graphics, which included marital status, education,
age, sex, and presence of health insurance. Comor-
bid illnesses were grouped into one of three comor-
bidity indexes—cardiovascular, non-cardiovascular,
and gastrointestinal. The cardiovasular comorbid-
ity index had the sum of the following conditions
reported by the patient: hypertension, angina, con-
gestive heart failure, previous myocardial infection,
and stroke. The non-cardiovascular index had 
the sum of the following conditions reported by 
the patient: diabetes, asthma/chronic obstructive
pulmonary disease, Crohn’s disease, any cancer, 
sciatica, osteoporosis, sleep problems, and depres-
sion. The gastrointestinal-related comorbidity index
had the sum of the following conditions reported
by the patient: history of ulcers, gastrointestinal
bleeding, abdominal pain, or other. Additional
characteristics obtained at the baseline were
site/type of musculoskeletal disease including
osteoarthritis of hip/knee and hand/wrist, rheuma-
toid arthritis, and lumbago. Potential arthritis-
medication-related adverse effects had the sum of
the following symptoms reported by the patient:
pain in upper stomach, burping/belching, heart-
burn, bloating, sour taste, nausea, and bad breath.
Finally, health utilization was obtained, which
included the number of medications taken at 12
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months, and the sum of the following tasks patients
reported needing assistance with: arising, dressing
and/or grooming, eating, walking, hygiene, gripping
and/or opening things, reaching, and doing errands
and/or chores.
To assess for site-speciﬁc confounding, one-way
analysis of variance was performed using change in
PCS and change in MCS as the dependent variables
with site as the independent variables.
Results
A total of 461 patients initially were enrolled in 
the study. A total of 388 patients provided baseline
and 12-month data. Descriptive information on the
study population is shown in Table 1. The mean age
of study participants was 59.2 years. Osteoarthritis
and low back pain were the most common self-
reported musculoskeletal disorders, followed by
rheumatoid arthritis. Hypertension was the most
common comorbidity reported (45%), followed 
by sciatica (34%). Nearly one-quarter of patients
(25%) reported having stomach-related problems,
sleep problems (25%), or depression (23%). No sig-
niﬁcant differences were observed for changes in
PCS or MCS between sites involved in the study.
Information on the DRPs identiﬁed by commu-
nity pharmacists is shown in Table 2. Of the cumu-
lative 926 DRPs reported during the 12 months, the
most common identiﬁed included needs additional
drug therapy (32.8%), adverse drug reaction
(17.3%), inappropriate compliance (15.9%), dose
too low (15.1%), and wrong drug (9.5%). Data on
DRP outcomes were available for 758 (82.0%) of
the 926 cumulative DRPs identiﬁed. By 12 months,
536 (70.7%) of the DRPs for which an outcome
was reported were resolved or improved, while 209
(27.6%) remained unchanged or stable. Only 13
(1.7%) of DRPs were reported as worsened.
In the univariate analyses, education was signif-
icantly positively associated with change in MCS 
(P = .038), while rheumatoid arthritis (P = .008)
and number of medications (P = .022) were signif-
icantly negatively associated with change in PCS.
As shown in Tables 3 and 4, the overall regres-
sion models were signiﬁcant for the PCS and MCS
Table 1 Demographics of study participants
Variable Frequency (%)*
Age (years)
Mean ± SD 59.2 ± 13.5
Range 19–94
Marital status
Married 251 (64.7)
Other 136 (35.3)
Education level
<4-year college degree 304 (78.6)
≥4-year college degree 83 (21.4)
Sex
Men 116 (29.9)
Women 272 (70.1)
Health insurance
Yes 369 (95.1)
No 18 (4.9)
Site of disease†
OA, hip/knee 223 (57.5)
OA, hand/wrist 179 (46.1)
Rheumatoid arthritis 74 (19.1)
Low back pain 208 (53.6)
Smoking status
Yes 49 (12.7)
No 338 (87.3)
Number of prescription medications
0 5 (1.3)
1 76 (19.6)
2 119 (30.7)
3 85 (21.9)
4 56 (14.4)
5 28 (7.2)
≥6 19 (4.9)
Standardized PCS‡
Baseline mean (SD) 34.41 (10.11)
Range 12.76–57.34
12-month mean (SD) 37.32 (10.89)
Range 11.88–60.25
Standardized MCS‡
Baseline mean (SD) 48.78 (10.63)
Range 11.55–72.22
12-month mean (SD) 52.11 (10.49)
Range 17.26–74.20
*Frequency may not total 388 because of missing data.
†Conditions are not mutually exclusive.
‡Higher scores represent better health status.
Abbreviation: OA, osteoarthritis.
Table 2 Cumulative (12-month) drug-related problems
identiﬁed during the study (Npatients = 388)
Description Frequency (%)
Drug-related problem
Needs additional drug therapy 304 (32.8)
Adverse drug reaction 160 (17.3)
Inappropriate compliance 147 (15.9)
Dose too low 140 (15.1)
Wrong drug 88 (9.5)
Unnecessary drug therapy 50 (5.4)
Dose too high 37 (4.0)
Diseases affected
Osteoarthritis 316 (33.8)
Rheumatoid arthritis 93 (9.9)
Low back pain 80 (8.6)
Osteoporosis 69 (7.4)
Stomach-related problems 65 (7.0)
Cardiovascular problems 53 (5.7)
Anxiety/depression 46 (4.9)
Other 213 (22.8)
Outcome*
Resolved/improved 536 (70.7)
Unchanged/stable 209 (27.6)
Worsened 13 (1.7)
Note: For Frequency, Npatients is the total number of patients presenting for the
12-month visit and Total NDRPs is the total number of drug-related problems
identiﬁed during the study.
Total NDRPs = 926.
*Information on outcome was available for 758 of the 926 total DRPs 
identiﬁed.
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change scores, respectively. The R2 for the PCS
change model was .069 (F = 2.107; P < .05). Sig-
niﬁcant associations were found for four variables.
Two types of DRPs showed signiﬁcant negative
associations with change in PCS: wrong drug and
needs additional drug therapy. No DRP outcome
variable showed a signiﬁcant correlation with
change in the PCS score. Two baseline characteris-
tic variables, self-reported rheumatoid arthritis and
number of medications, were signiﬁcantly nega-
tively associated with change in PCS score.
The R2 for the regression of the change in mental
component score was 0.061 (F = 2.006; P < .05).
Signiﬁcant associations were identiﬁed for four vari-
ables. One type of DRP, needs additional drug
therapy, was negatively associated with change in
MCS score. In addition, the frequencies of both
drug-related problem resolution and drug-related
problem improvement was positively related to the
change in mental component score. Education level
was positively associated with change in MCS.
Discussion
Our results demonstrate that certain DRPs are 
associated with reduced HRQoL in community-
dwelling, ambulatory arthritis, and low back pain
sufferers. Two types of DRPs—“wrong drug” and
“needs additional drug therapy”—were associated
with reduced physical health summary scores, while
one DRP—“needs additional drug therapy”—was
associated with reduced mental health summary
scores from the SF-36 health survey.
Drug-related problems can result in reduced
quality of life for several reasons. For example,
wrong drug could encompass a myriad of problems
such as drug interactions, condition being refrac-
tory to the drug, contraindications present, or drug
not effective for the condition [9]. The sequelae of
such DRPs can result in continued symptoms of the
disease or a new set of symptoms, which could con-
tribute to reduced quality of life. It is not uncom-
mon for a patient with osteoarthritis to use a
number of different drugs (e.g., NSAIDs) to ﬁnd one
that is effective and also tolerable.
The DRP needs additional drug therapy reﬂects
either the presence of an underlying condition that
is not recognized or treated or that the patient could
be receiving treatment but remain symptomatic. In
the case of arthritis sufferers, this could be a patient
taking the maximum dose of an anti-inﬂammatory
agent but still experiencing pain, or it could be 
the case where one of their comorbid illnesses of 
signiﬁcant health burden is suboptimally treated.
Another recent study using community pharmacists
to monitor drug therapy similarly found the need
for additional therapy to be the most common DRP
[28].
As expected, some of the baseline characteris-
tic variables showed signiﬁcant correlations with
changes in the physical component summary and
mental component summary scores. The presence
of rheumatoid arthritis was negatively associated
with change in the PCS. The progressive and
destructive nature of rheumatoid arthritis is likely
to be manifest as physical functioning and pain,
which are two primary domains within the PCS. It
has been previously shown that arthritis sufferers
have lower HRQoL compared to their healthy
counterparts [17]. The change in PCS was also sig-
Table 3 Multivariate analysis of change in SF-36 PCS
Type of variable Beta P value
Drug-related problem
Needs additional drug therapy -0.146 .038*
Adverse drug reaction -0.015 .800
Inappropriate compliance -0.029 .654
Dose too low -0.064 .302
Wrong drug -0.141 .015*
Unnecessary drug therapy -0.001 .990
Dose too high -0.066 .228
Drug-related problem outcome
Resolved 0.124 .071
Improved 0.034 .647
Unchanged 0.067 .325
Worsened -0.055 .301
Site/type of musculoskeletal disease
Rheumatoid arthritis -0.139 < .01†
Health utilization
Number of medications -0.100 .047*
Note: F = 2.107, P = 0.013, and R2 = 0.069 apply to entire model.
*Signiﬁcance level .05.
†Signiﬁcance level .01.
Table 4 Multivariate analysis of change in SF-36 MCS
Type of variable Beta P value
Drug-related problem
Needs additional drug therapy -0.183 .01†
Adverse drug reaction -0.032 .575
Inappropriate compliance -0.121 .066
Dose too low -0.049 .435
Wrong drug -0.108 .063
Unnecessary drug therapy 0.052 .345
Dose too high -0.067 .220
Drug-related problem outcome
Resolved 0.154 .05*
Improved 0.223 < .01†
Unchanged 0.100 .146
Worsened 0.020 .712
Demographics
Education 0.114 .026*
Note: F = 2.006, P = 0.023, and R2 = 0.061 apply to entire model.
*Signiﬁcance level .05.
†Signiﬁcance level .01.
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niﬁcantly negatively associated with the number of
medications a patient was receiving. A greater
number of medications may indicate poorer overall
health, as well as associated lower physical health.
In addition, because polypharmacy is often present
in patients with chronic disease, the adverse effects
of multiple medications could have themselves con-
tributed to a lower PCS.
The level of education was positively associated
with the change in MCS score. Perhaps attaining 
a higher level of education allows people to enter
occupations that are associated with better mental
health. Or, higher education could be related to
better access to medical care, although most
patients in the study reported having health 
insurance.
Positively addressing DRPs can be an impor-
tant step to improving HRQoL. Resolution and
improvement of DRPs was associated with signiﬁ-
cantly improved MCS scores, but the association
did not reach statistical signiﬁcance for PCS scores.
It is possible that the act of following the popula-
tion of patients over time helped them to feel better
emotionally because greater attention was being
given to their condition, but ultimately did not
result in signiﬁcant improvements in physical health
for other reasons related to lack of drug efﬁcacy or
exhausting available resources and treatment
options.
Many of the DRPs identiﬁed in the study could
be resolved or improved when health care practi-
tioners systematically monitored patient-reported
outcomes. This study is an example of one innova-
tive method to monitor drug therapy in an attempt
to minimize the negative effects of DRPs. However,
it was limited in that the process was entirely driven
by the community pharmacist. Another possible
approach is to utilize a structured multidisciplinary
team that combines the expertise and availability of
a number of health care practitioners. For example,
pharmacists could be used as a point person in mon-
itoring for DRPs and then communicating their
ﬁndings to physicians. Physicians could oversee 
any adjustments in drug therapy or other changes
intended to resolve a DRP. Previous studies have
found that such a team approach can reduce the
number of DRPs faced by patients [29,30].
Pharmacists practicing in community settings
performed the drug therapy monitoring in our
program. These individuals are well positioned 
to screen for potential and existing DRPs [31].
Increased utilization of pharmacists in nondispens-
ing roles has been called for nationally as one strat-
egy to improve medication use outcomes in
addressing the recent Institute of Medicine report
on medical errors [32]. Because they are the most
accessible health care professional for many pa-
tients [33], pharmacists occupy a unique place in
the health-care system that enables them to screen
for drug interactions and adverse reactions, monitor
therapeutic efﬁcacy, and identify potential or exist-
ing DRPs.
There are several limitations to our study that
must be noted. First, it was an observational study
without a control group. We were not able to iden-
tify patient level factors associated with DRPs in
DRP sufferers versus nonsufferers. Second, we did
not examine change in HRQoL as a function of 
the total number or speciﬁc type of DRP resolved.
Certain DRPs may result in more signiﬁcant health
burden than others; interventions directed at the
more signiﬁcant DRP could result in proportion-
ately greater changes in health status. Third,
although we note an association between decreased
PCS and DRPs, our data are insufﬁcient to explain
whether this decrease is caused by DRPs or whether
DRPs serve as a proxy for underlying medical or
functional conditions associated with decreased
physical HRQoL. Fourth, although the SF-36 is
widely used to monitor HRQoL of populations, its
utility at the patient level to help direct health care
interventions has been questioned [34–37]. Other
studies utilizing pharmacist management of drug
therapy, which measured HRQoL using the SF-36
survey, have found a similar lack of effect, again
possibly owing to the instrument not being sensitive
enough to measure these changes [38–42]. The use
of disease-speciﬁc health instruments (e.g., Arthritis
Impact Measurement Scale) or the development of
an health instrument speciﬁc for DRPs might be
more useful in measuring the impact of DRPs on
HRQoL.
Despite limitations to our study, it is apparent
that DRPs contribute to reduced HRQoL in arthri-
tis and low back pain sufferers. Given the multi-
faceted nature of drug therapy for chronic diseases,
future research should examine where the most
appropriate place is within the health care system
to systematically and efﬁciently monitor drug
therapy to identify and prevent DRPs from occur-
ring. Future research also should examine whether
changes in health care at the system level or at the
site level are needed to most efﬁciently resolve DRPs
when they develop. It appears that resolving DRPs
is one step in helping improve HRQoL. This
improved HRQoL may have important implica-
tions on future health resource utilization in this
cohort of patients. Clinicians should actively screen
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for potential and existing DRPs in patients with
musculoskeletal disorders and resolve them accord-
ingly.
Conclusions
Two DRPs, wrong drug and needs additional drug
therapy, are signiﬁcantly negatively associated with
self-reported physical health in community-
dwelling arthritis and low back pain sufferers, and
the DRP needs additional therapy is also signiﬁ-
cantly associated with reduced self-reported mental
health. Improvement and resolution of DRPs in this
cohort is associated with signiﬁcant improvements
in mental health.
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